AxoGen First Quarter 2013 Results and Conference Call
May 01, 2013 at 10:00 AM EDT
Welcome to AxoGenInc.com! On behalf of the Directors, Executive Team and Employees of AxoGen, I am delighted to introduce you to our new Investor Relations portal. We are committed to providing you with current, accessible information about the Company to help you manage your investment and understand our market, our business, our technology and our strategies.
AxoGen Corporation was incorporated in 2002 and became the operating subsidiary of AxoGen, Inc. (formerly LecTec Corporation incorporated in 1977) through a merger in September 2011. AxoGen's principal executive office is located in Alachua, FL, a growing center of biotech and regenerative medicine adjacent to Gainesville, FL and the University of Florida. AxoGen, Inc. stock trades on the OTCBB under the symbol "AXGN".
Each year, more than 1.4 million people suffer traumatic peripheral nerve injuries in the U.S. Beyond traumatic injuries, nerve reconstruction is often required after nerve damage from surgical intervention, chronic compression injuries or repetitive stress. As a leader in the nerve reconstruction and regeneration space, AxoGen is strongly committed to developing, commercializing and distributing a portfolio of technologies that will provide patients and physicians with improved options for the treatment of peripheral nerve injuries.
We believe our product portfolio provides the nerve reconstruction market with off-the-shelf products for a variety of nerve repair and nerve reconstruction procedures without the cost, risk of complications and loss of function associated with autografts. Our product portfolio currently includes Avance® Nerve Graft, which we believe is the first and only commercially available allograft nerve for bridging nerve discontinuities, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.
While there is a compelling value proposition for our technologies, to date we have accessed only a small percentage of this market. As we move forward, we intend to use our financial resources to increase value for shareholders and provide additional treatment options for patients and physicians. Our investments will focus on five key areas:
- Providing national coverage by increasing sales reach and improving sales support and resources;
- Commercialization strategies to increase technology awareness and adoption;
- Expanding clinical and scientific data regarding the performance of AxoGen products;
- Optimizing manufacturing processes;
- R&D investment and pipeline development.
As always, our investment choices will be guided by our commitment to operate in an honest and ethical manner. We are a company that consistently recognizes the importance of the work we do and we consider the impact on the customer in every decision. We believe that these approaches will strengthen our ability to maintain a competitive advantage and enable AxoGen to solidify its position as a leader in the field of peripheral nerve reconstruction and regeneration.
Finally, I would like to recognize the dedication and enthusiasm of our employees. Their contributions are invaluable to the success of AxoGen.
We are proud to be a part of the regenerative medical community and excited to continue development of solutions for peripheral nerve injuries. Thank you for your support.
Chief Executive Officer